Science

Final Overall Survival in the Phase III FALCON Trial

John F.R. Robertso

Jan 22, 2025, 11:03

Final Overall Survival in the Phase III FALCON Trial

Kristina Jankovic, Medical Oncology Resident at the University Clinical Center Niš, shared an article by John F.R. Robertso on X:

“Final OS analysis from FALCON:

No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ ABC.
15% risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months).”

Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.

Authors: John F.R. Robertso, et al.

Final Overall Survival in the Phase III FALCON Trial

anastrozole Breast Cancer cancer FALCON fight against cancer Fulvestrant Global fight against cancer John F.R. Robertso Kristina Jankovic MedOnc OncoDaily Oncology University Clinical Center Niš

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer